Category Archives: Cancer Research

Eric Lefkofsky’s Struggle toward modernizing Cancer Treatment

Eric Lefkofsky is one of the founders of Groupon and also one of the most influential technology figures in Chicago. Eric Lefkofsky is philanthropic who has contributed lost of dollars to support cancer research. Currently, he is among the team who are looking to pack lots of effort toward innovating smarter approaches in handling cancer and cancer patients. It has been reported that since he ceased working in Groupon, Eric Lefkofsky is working at Tempus, a health startup that is aiming at modernizing cancer treatment.

Operations of Tempus

Tempus is secretly operating under the shadow of Lightbank which is another firm that was founded by Eric Lefkofsky. This implies that he has done a great job in ensuring that the company has enough resources to enable it to undertake its core duties. A close research of the Tempus reveals that Eric Lefkofsky could be the president of the Company. It is however not clear the number of hours that Eric Lefkofsky spends in the company, and it appears like he is not willing to disclose it anytime soon.

Molecular Therapies

Tempus’ website states that its primary duty is to help doctors make the most accurate medical decisions which are enhanced by generic code in the context of molecular therapies. By using genomic sequencing, Tempus is able to generate data that can be used to understand the right procedures to be given to cancer patients to avoid errors in handling them. This technology is believed to augment the doctor’s understanding of the patients’ tumour. Tempus uses and collects data that is used in analyzing numerous amounts of genomic information with the aim of uncovering opportunities that are used to assist physicians in making informed decisions when dealing with patients infected with cancer.

Eric Lefkofsky is one of the most dedicated individuals who is working tirelessly to ensure that cancer is brought under human control. It is worth noting that Eric Lefkofsky is such a skilled guy who can work with big organizations; instead, he spends his time doing something unique that would eventually save lives. That is why he has become so influential among the people who are looking to emulate his skills and art of leveraging technology with a positive mindset.

To know more click here

Dr. Siegall, Clay Chief Executive Officer, and Co-founder of Seattle Genetics

Dr. Siegall Clay is the current serving CEO, President, and Co-founder of Seattle Genetics. He has worked in different research institutes and organizations, before co-founding Seattle Genetics. He attained his B.S in Zoology from Maryland University, and later on a Ph.D. specializing in Genetics from George Washington University. He also serves on the board of Directors in two different private companies, Mirna Therapeutics, and Alder Biopharmaceuticals. He kicked off his career serving at National Institutes of Health from the year 1988 to 1991 and later worked at Bristol-Myers Squibb pharmaceutical Research Institute from the year 1991 to 1997.

Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.

Seattle Genetics was founded in the year 1998, with Dr. Siegall as the President. The company is a biotechnology company that works on developing preclinical and clinical products, and research that is devoted to Cancer research. The company has earned good reputation over the years as the leading antibody technologies. His leadership has helped the company attain numerous strategic licenses with its technology. The licenses include Abvie, Pfizer, and Genentech (Roche), generating over 300$ million Dollar in revenue, since its inception. Seattle Genetics technology has earned and maintained a huge share in the clinical development programs, having over 20 ADCs in the development of clinical products all across the program.

Prior to Seattle Genetics getting numerous collaborations, the company achieved an exclusive international strategic collaboration agreement with Genentech worth over $860 million for SGN-40. The ADCs technology is designed to not affect non-targeted cells. It has worked to reduce the numerous side effects that came with the traditional Chemotherapy but also maintaining high antitumor activity. The company leads in ADCs with their program ADCETRIS (brentuximab vedotin), which opened a new class in the ADCs technologies. Not only is the program broad and recommended for clinical development programs but also runs a huge potential of soon becoming the foundation for treatment of Hodgkin Lymphoma, B-cell lymphomas, CD-30 expressing lymphomas, and B-cell lymphomas.

The collaboration with Takeda helped Seattle Genetics achieve full rights with its ADCETRIS program in both Canada and the United States. Takeda has the upper hand in the commercialization rights, maintaining them exclusively in all other countries.